Emma Guttman-Yassky, Paola Facheris, Pedro Jesus Gomez-Arias, Ester Del Duca, Joel Correa Da Rosa, Stephan Weidinger, Robert Bissonnette, April W Armstrong, Julien Seneschal, Kilian Eyerich, Yeriel D Estrada, Swaroop N Bose, Dan Xu, Allshine Chen, Svitlana Tatulych, Erman Güler, Gary Chan, Karen M Page, Urs Kerkmann
BACKGROUND: This is the first report on the effects of abrocitinib, a Janus kinase 1-selective inhibitor, on the expression of skin biomarkers in patients with moderate-to-severe atopic dermatitis (AD). METHODS: JADE MOA (NCT03915496) was a double-blind Phase 2a trial. Adults were randomly assigned 1:1:1 to receive monotherapy with once-daily abrocitinib 200 mg, abrocitinib 100 mg, or placebo for 12 weeks. The primary endpoint was change from baseline in markers of inflammation (matrix metalloproteinase [MMP]-12), epidermal hyperplasia (keratin-16 [KRT16]), T-helper 2 (Th2) immune response (C-C motif chemokine ligand [CCL]17, CCL18, and CCL26), and Th22 immune response (S100 calcium binding protein A8, A9, and A12 [S100A8, S100A9, and S100A12]) in skin through 12 weeks...
December 18, 2023: Allergy